About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy, Safety, and Pharmacokinetics of QAW039 | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT01253603

Efficacy, Safety, and Pharmacokinetics of QAW039

This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.

Lead sponsor: Novartis Pharmaceuticals•18 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with a medical history of mild to moderate persistent allergic asthma.
•Patients must weigh at least 45 kg to participate in the study, and must have abody mass index (BMI) of \>17 kg/m2.
•Female patients must be surgically sterilized, postmenopausal or using a double-barrier method of contraception

Exclusion Criteria

•Women of child-bearing potential.
•Smokers defined as history of smoking in the previous 6 months or a smoking history of more than 10 pack years, a pack year being defined as smoking the equivalent of 20 cigarettes - a pack - every day for the period of 1 year
•Patients with severe persistent asthma

Related studies

Active Not Recruiting

Asthma Research in Children and Adolescents

NCT04480242 · Persistent Asthma, Asthma in Children, and more

COMPLETEDPhase 2

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

NCT04773678 · Moderate to Severe Persistent Asthma

The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma

NCT05632549 · Moderate Persistent Asthma

COMPLETEDPhase 2

Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)

NCT01343745 · Mild Persistent Asthma

Expressions of TRPV1 in Airway of Asthmatics

NCT02952066 · Moderate Persistent Asthma, Severe Persistent Asthma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 19, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment170

Start dateNov 2010

Last updatedDec 19, 2020

Condition

Persistent Asthma

Locations shown

Novartis Investigative Site

Encinitas, California

Novartis Investigative Site

Huntington Beach, California

Novartis Investigative Site

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions